- Title: U.S. administers 364.8 mln doses of COVID-19 vaccines - CDC
- Date: 26th August 2021
- Summary: BAY SHORE, NEW YORK, UNITED STATES (FILE - MARCH 3, 2021) (REUTERS) BOX OF JOHNSON & JOHNSON VACCINE VIALS ON TABLE NEXT TO SANITIZER BOTTLE JOHNSON & JOHNSON VACCINE VIALS ON TABLE
- Embargoed: 9th September 2021 10:34
- Keywords: CDC COVID-19 Johnson & Johnson Pfizer/BioNTech U.S. Centers for Disease Control and Prevention United States coronavirus vaccines
- Location: VARIOUS
- City: VARIOUS
- Country: USA
- Topics: Health/Medicine,United States
- Reuters ID: LVA005ERX3ADJ
- Aspect Ratio: 16:9
- Story Text: The United States has administered 364,842,701 doses of COVID-19 vaccines in the country as of Wednesday (August 25) morning and distributed 430,118,615 doses, the U.S. Centers for Disease Control and Prevention said.
Those figures are up from the 363,915,792 vaccine doses that the CDC said had gone into arms by Aug. 24 out of 428,529,385 doses delivered.
The agency said 202,500,853 people had received at least one dose while 171,773,370 people are fully vaccinated as of Wednesday.
The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech, as well as Johnson & Johnson's one-shot vaccine as of 6:00 a.m. ET on Wednesday.
U.S. health regulators could approve a third COVID-19 shot for adults beginning at least six months after full vaccination instead of the previously announced eight-month gap, the Wall Street Journal reported on Wednesday.
Approval of boosters for three COVID-19 shots being administered in the United States - those manufactured by Pfizer Inc and partner BioNTech SE, Moderna Inc and Johnson & Johnson - is expected in mid-September, the report said, citing a person familiar with the plans.
Pfizer and BioNTech have already started the application process for the approval of its booster shot in people 16 and older, saying it spurs a more than three-fold increase in antibodies against the coronavirus.
Earlier this week, U.S. regulators granted full approval to Pfizer's two-dose vaccine. Moderna said on Wednesday it had completed the real-time review needed for full approval for its jab in people 18 and above.
The CDC said the government's plan to administer booster shot depends on pending action from the Food and Drug Administration and recommendation to it from the Advisory Committee on Immunization Practices.
The FDA, however, reiterated its joint statement from last week that said the government was gearing up to roll out the third shot from mid-September to Americans who had their initial course of two-dose vaccines made by Moderna and Pfizer more than eight months ago.
The rollout would start if the FDA and the CDC decide that boosters are needed, U.S. officials had said.
(Production: Njuwa Maina) - Copyright Holder: FILE REUTERS (CAN SELL)
- Copyright Notice: (c) Copyright Thomson Reuters 2021. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None
